A Phase 1 interventional study of CDX-0159 and Normal Saline in Chronic Spontaneous Urticaria, sponsored by Celldex Therapeutics. Completed at 14 sites in 2 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-07-19.
Sponsored by Celldex Therapeutics · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 64 studies in Chronic Urticaria with a site in United States — 9 open to participants now, 17 under way, 6 of them phase 3. Chronic Urticaria · United States.
Among the 64 studies in Chronic Urticaria with a site in United States, this one is the 43rd largest by enrollment of the 58 interventional ones that give a count, is one of 3 that started in 2020, is one of 5 in phase 1, and was the 28th registered.
197 studies on the registry are indexed under Chronic Urticaria; 48 are open to participants now.
Browse Chronic Urticaria studies →9 of the 64 studies in Chronic Urticaria with a site in United States are open now. Recruiting first, the newest first:
Calixis Inc. · Sites in United States
Ages 18–85
Enanta Pharmaceuticals, Inc · Sites in United States
Ages 18–65 · Healthy volunteers
Novartis Pharmaceuticals · Sites in United States
Ages 18+
Novartis Pharmaceuticals · Sites in United States
Ages 18–100
Novartis Pharmaceuticals · Sites in United States
Ages 18–100
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 25 Chronic Urticaria studies recruiting now, 11 (44%) set no upper age limit and 10 (40%) stop at 75 or younger; 1 takes children under 18; 6 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
64 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 25 · Phase 3 22 · Phase 4 4
First in 2008; this study’s year is marked. 3 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 45 is below the median of 80 across 147 interventional studies indexed under Chronic Urticaria.
Median enrollment 132 across the 58 interventional studies, 428 across the 6 observational. Of the 44 that completed or were terminated, 30 (68%) have results posted.
This tab as a report to print or save as PDF → With an account.
52 of 64 have an industry lead sponsor. The 10 most frequent:
Celldex Therapeutics is the lead sponsor of 45 studies on the registry; 3 are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 1 (7%) have results posted.
Celldex Therapeutics has 5 studies filed under Chronic Urticaria — fewer than ten, so there is no comparison to draw.
6 of the studies in Chronic Urticaria with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06868212Phase 3Novartis PharmaceuticalsA Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistamines | 2027-02-22 |
| NCT07540910Enanta Pharmaceuticals, IncA Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of EDP-978 in Healthy Adults | 2026-11 |
| NCT07219615PfizerA Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults. | 2026-12-25 |
| NCT06931405Blueprint Medicines CorporationStudy of BLU-808 in Chronic Inducible Urticaria (CIndU) and Chronic Spontaneous Urticaria (CSU) | 2026-12-31 |
| NCT06927999ARS Pharmaceuticals, Inc.An Outpatient Study of the Efficacy of ARS-2 in Patients With Chronic Spontaneous Urticaria | 2027-06 |
Add all 6 to your calendar (.ics) → With an account.
Among the 64 studies in Chronic Urticaria with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a study to determine the safety of multiple doses of CDX-0159 in patients with Chronic Spontaneous Urticaria.
The purpose of the study is to explore the safety, pharmacodynamics, and pharmacokinetics of ascending doses of CDX-0159 in patients with Chronic Spontaneous Urticaria who remain symptomatic despite treatment with antihistamines.
There is a screening period of up to 2 weeks, a 12-week double-blind treatment period and a 12-week follow-up period after treatment. Patients will receive multiple doses of CDX-0159 or placebo as add on therapy to their antihistamine.
Key Inclusion Criteria:
Diagnosis of chronic spontaneous urticaria (CSU) despite the use of H1-antihistamines alone or in combination with H2-antihistamines and/or leukotriene receptor antagonists, as defined by:
Key Exclusion Criteria:
There are additional criteria that your study doctor will review with you to confirm you are eligible for the study.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CDX-0159 every 4-8 weeks
Drug: CDX-0159
Normal saline every 4-8 weeks
Drug: Normal Saline
Administered intravenously
Administered intravenously
Safety as assessed by the incidence and severity of adverse events
Safety of multiple, ascending doses of CDX-0159 as determined by drug related adverse events
Time frame: From Day 1 (first dose) to Day 169 (last follow-up visit)
Pharmacokinetic evaluation
CDX-0159 serum concentrations will be measured at specified visits
Time frame: From Day 1 (before first dose) to Day 169 (last follow-up visit)
Pharmacodynamic evaluation
The change from baseline for Urticaria Activity Score (UAS7) in patients who received CDX-0159 vs. placebo
Time frame: From Day 1 (first dose) to Day 169 (last follow-up visit)
Pharmacodynamic evaluation
The change from baseline for Hives Severity Score (HSS7) in patients who received CDX-0159 vs. placebo
Time frame: From Day 1 (first dose) to Day 169 (last follow-up visit)
Pharmacodynamic evaluation
The change from baseline for Itch Severity Score (ISS7) in patients who received CDX-0159 vs. placebo
Time frame: From Day 1 (first dose) to Day 169 (last follow-up visit)
Pharmacodynamic evaluation
The change in baseline for Urticaria Control Test (UCT) in patients who received CDX-0159 vs. placebo
Time frame: Day 1 (first dose) to Day 169 (last follow up visit)
Pharmacodynamic evaluation
The effect of CDX-0159 on stem cell factor levels
Time frame: From Day 1 (before first dose) to Day 169 (last follow-up visit)
Pharmacodynamic evaluation
The effect of CDX-0159 on tryptase
Time frame: From Day 1 (before first dose) to Day 169 (last follow-up visit)
Safety evaluation
Assessment of immunogenicity by measuring the development of anti- CDX-0159 antibodies
Time frame: From Day 1 (before dosing) to Day 169 (last follow-up visit)
Ran from Sep 2020 to primary completion in Jan 2023, 27 months.
Of 15 phase 1 interventional studies under Chronic Urticaria, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 21. This study's 27 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Barzolvolimab